IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10793579 B1

PDFFull Text
Date of Patent:
Oct. 06, 2020

Filed:

May. 14, 2019

Bicyclic-fused heteroaryl or aryl compounds

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

John David Trzupek, Arlington, MA (US);

Katherine Lin Lee, West Newton, MA (US);

Mark Edward Bunnage, Concord, MA (US);

Seungil Han, Mystic, CT (US);

David Hepworth, Concord, MA (US);

Frank Eldridge Lovering, Acton, MA (US);

John Paul Mathias, Concord, MA (US);

Nikolaos Papaioannou, Newton, MA (US);

Betsy Susan Pierce, East Lyme, CT (US);

Joseph Walter Strohbach, Wentzville, MO (US);

Stephen Wayne Wright, Old Lyme, CT (US);

Christoph Wolfgang Zapf, Marlborough, MA (US);

Lori Krim Gavrin, Villanova, PA (US);

Arthur Lee, San Carlos, CA (US);

David Randolph Anderson, Salem, CT (US);

Kevin Joseph Curran, Somerset, NJ (US);

Christoph Martin Dehnhardt, Burnaby, CA;

Eddine Saiah, Brookline, MA (US);

Joel Adam Goldberg, New Orleans, LA (US);

Xiaolun Wang, San Diego, CA (US);

Horng-Chih Huang, Chesterfield, MO (US);

Richard Vargas, Bedford, MA (US);

Michael Dennis Lowe, White Plains, NY (US);

Akshay Patny, Waltham, MA (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:

James T. Wasicak

Primary Examiner:

Zinna Northington Davis

Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); C07D 491/056 (2006.01); C07F 7/18 (2006.01); C07D 405/14 (2006.01); C07D 217/02 (2006.01); C07D 217/22 (2006.01); C07D 217/24 (2006.01); C07C 69/94 (2006.01); C07D 239/86 (2006.01); C07D 239/88 (2006.01); C07D 263/24 (2006.01); C07D 207/273 (2006.01); C07D 498/04 (2006.01); C07D 209/52 (2006.01); A61K 31/4015 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); C07D 207/26 (2006.01); C07D 215/48 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 407/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 487/04 (2006.01); A61K 31/40 (2006.01); C07D 207/08 (2006.01); C07D 207/267 (2006.01);
U.S. Cl.
CPC ...
C07D 491/056 (2013.01); A61K 31/40 (2013.01); A61K 31/4015 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); C07C 69/94 (2013.01); C07D 207/08 (2013.01); C07D 207/26 (2013.01); C07D 207/267 (2013.01); C07D 207/273 (2013.01); C07D 209/52 (2013.01); C07D 215/48 (2013.01); C07D 217/02 (2013.01); C07D 217/22 (2013.01); C07D 217/24 (2013.01); C07D 239/86 (2013.01); C07D 239/88 (2013.01); C07D 263/24 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01); C07F 7/1804 (2013.01);
Abstract

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Find Patent Forward Citations

Loading…